Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31


First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, Mazzaferro V, Trojan J, Zhu AX, Yoon JH, Sharma S, Lin ZZ, Chan SL, Faivre S, Feun LG, Yen CJ, Dufour JF, Palmer DH, Llovet JM, Manoogian M, Tugnait M, Stransky N, Hagel M, Kohl NE, Lengauer C, Sherwin CA, Schmidt-Kittler O, Hoeflich KP, Shi H, Wolf BB, Kang YK.

Cancer Discov. 2019 Dec;9(12):1696-1707. doi: 10.1158/2159-8290.CD-19-0555. Epub 2019 Oct 1.


Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.

Hatlen MA, Schmidt-Kittler O, Sherwin CA, Rozsahegyi E, Rubin N, Sheets MP, Kim JL, Miduturu C, Bifulco N, Brooijmans N, Shi H, Guzi T, Boral A, Lengauer C, Dorsch M, Kim RD, Kang YK, Wolf BB, Hoeflich KP.

Cancer Discov. 2019 Dec;9(12):1686-1695. doi: 10.1158/2159-8290.CD-19-0367. Epub 2019 Oct 1.


MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.

Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA, Montagut C, Di Nicolantonio F, Nering R, Bardelli A.

Sci Transl Med. 2016 Feb 3;8(324):324ra14. doi: 10.1126/scitranslmed.aad5640.


Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic.

Kearns JD, Bukhalid R, Sevecka M, Tan G, Gerami-Moayed N, Werner SL, Kohli N, Burenkova O, Sloss CM, King AM, Fitzgerald JB, Nielsen UB, Wolf BB.

Mol Cancer Ther. 2015 Jul;14(7):1625-36. doi: 10.1158/1535-7163.MCT-14-0772. Epub 2015 Apr 24.


On the edge of validation--cancer protease fibroblast activation protein.

Wolf BB, Quan C, Tran T, Wiesmann C, Sutherlin D.

Mini Rev Med Chem. 2008 Jun;8(7):719-27. Review.


Ala657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization.

Meadows SA, Edosada CY, Mayeda M, Tran T, Quan C, Raab H, Wiesmann C, Wolf BB.

Biochemistry. 2007 Apr 17;46(15):4598-605. Epub 2007 Mar 24.


Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.

Tran T, Quan C, Edosada CY, Mayeda M, Wiesmann C, Sutherlin D, Wolf BB.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1438-42. Epub 2006 Dec 1.


Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity.

Edosada CY, Quan C, Tran T, Pham V, Wiesmann C, Fairbrother W, Wolf BB.

FEBS Lett. 2006 Mar 6;580(6):1581-6. Epub 2006 Feb 3.


Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity.

Edosada CY, Quan C, Wiesmann C, Tran T, Sutherlin D, Reynolds M, Elliott JM, Raab H, Fairbrother W, Wolf BB.

J Biol Chem. 2006 Mar 17;281(11):7437-44. Epub 2006 Jan 12.


Apoptosis: letting slip the dogs of war.

Wolf BB, Green DR.

Curr Biol. 2002 Mar 5;12(5):R177-9. Review.


Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity.

Wolf BB, Schuler M, Li W, Eggers-Sedlet B, Lee W, Tailor P, Fitzgerald P, Mills GB, Green DR.

J Biol Chem. 2001 Sep 7;276(36):34244-51. Epub 2001 Jun 27.


Granzyme B-mediated apoptosis proceeds predominantly through a Bcl-2-inhibitable mitochondrial pathway.

Pinkoski MJ, Waterhouse NJ, Heibein JA, Wolf BB, Kuwana T, Goldstein JC, Newmeyer DD, Bleackley RC, Green DR.

J Biol Chem. 2001 Apr 13;276(15):12060-7. Epub 2001 Jan 12.


Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome.

Beere HM, Wolf BB, Cain K, Mosser DD, Mahboubi A, Kuwana T, Tailor P, Morimoto RI, Cohen GM, Green DR.

Nat Cell Biol. 2000 Aug;2(8):469-75.


Bcl-xL does not inhibit the function of Apaf-1.

Newmeyer DD, Bossy-Wetzel E, Kluck RM, Wolf BB, Beere HM, Green DR.

Cell Death Differ. 2000 Apr;7(4):402-7.


Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation.

Wolf BB, Goldstein JC, Stennicke HR, Beere H, Amarante-Mendes GP, Salvesen GS, Green DR.

Blood. 1999 Sep 1;94(5):1683-92.


Suicidal tendencies: apoptotic cell death by caspase family proteinases.

Wolf BB, Green DR.

J Biol Chem. 1999 Jul 16;274(29):20049-52. Review. No abstract available.


Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis.

Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM.

J Biol Chem. 1999 Feb 19;274(8):5053-60.


Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner.

Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, Reed JC, Nicholson DW, Alnemri ES, Green DR, Martin SJ.

J Cell Biol. 1999 Jan 25;144(2):281-92.


Pro-caspase-3 is a major physiologic target of caspase-8.

Stennicke HR, J├╝rgensmeier JM, Shin H, Deveraux Q, Wolf BB, Yang X, Zhou Q, Ellerby HM, Ellerby LM, Bredesen D, Green DR, Reed JC, Froelich CJ, Salvesen GS.

J Biol Chem. 1998 Oct 16;273(42):27084-90.


Neurotrophin binding to human alpha 2-macroglobulin under apparent equilibrium conditions.

Wolf BB, Gonias SL.

Biochemistry. 1994 Sep 20;33(37):11270-7.


Alpha 2-macroglobulin and the alpha 2-macroglobulin receptor/LRP. A growth regulatory axis.

Gonias SL, LaMarre J, Crookston KP, Webb DJ, Wolf BB, Lopes MB, Moses HL, Hayes MA.

Ann N Y Acad Sci. 1994 Sep 10;737:273-90. Review. No abstract available.


Nerve growth factor-gamma activates soluble and receptor-bound single chain urokinase-type plasminogen activator.

Wolf BB, Vasudevan J, Henkin J, Gonias SL.

J Biol Chem. 1993 Aug 5;268(22):16327-31.


A comparison of academic performance of female and male optometry students at the University of Missouri-St. Louis.

Trick LR, Davis S, Wolf BB, Hirata M.

J Am Optom Assoc. 1988 Feb;59(2):89-92.


Supplemental Content

Support Center